Skip to content

Author

Sang Gyune Kim

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

MASLD VCTE-C cohort: a prospective multicenter study linking liver fibrosis to cardiovascular outcomes in patients with metabolic dysfunction–associated steatotic liver disease

Metabolic dysfunction–associated steatotic liver disease (MASLD) is associated with increased risk of cardiovascular disease (CVD). The MASLD vibration-controlled transient elastography (VCTE)-C cohort is designed to examine the relationships among VCTE-derived hepatic measures, coronary artery calcification, and l...

Young Chang, Young Kul Jung, Han-Ah Lee et al. · 0 citations
Open access Oct 2026

A Case of Fimasartan-Induced Liver Injury Proven by Rechallenge and Biopsy

Fimasartan is a widely used angiotensin II receptor blocker (ARB) known for its favorable safety profile. However, its hepatotoxic potential remains poorly characterized. We report a case of drug-induced liver injury (DILI) in a 79-year-old woman who developed jaundice and elevated liver enzymes after initiating fimasa...

Seryeong Kim, Jisoo Lee, Susie Chin et al. · 0 citations
Review Open access Sep 2026

High Treatment Adherence Is Associated With Lower Observed HCC Risk in Patients With Chronic Hepatitis B and Cirrhosis: A Nationwide Claims-Based Cohort Study.

Adherence to antiviral therapy is essential for viral suppression in chronic hepatitis B (CHB), yet its effect on hepatocellular carcinoma (HCC) remains uncertain. We examined the association between nucleos(t)ide analog (NA) adherence and HCC risk, focusing on tenofovir alafenamide (TAF) versus entecavir (ETV). Treatm...

Yoon E. Shin, Jae Young Kim, Jeong-Ju Yoo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.